Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-fludarabine
- Development stage
- Phase 1
- Lead developer
- GIP Cyceron
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
**18F-fludarabine** is a radiopharmaceutical agent derived from the purine analog fludarabine and labeled with the radioisotope fluorine-18. It is primarily used as a positron emission tomography (PET) imaging tracer for hematological malignancies such as lymphoma and chronic lymphocytic leukemia (CLL). The compound leverages the cellular uptake and accumulation properties of fludarabine, which are cell-cycle independent. Once inside cells, it is phosphorylated by deoxycytidine kinase to its active triphosphate form. The radiolabeling with fluorine-18 allows for high-sensitivity PET imaging of lymphoid tumors due to specific uptake in malignant lymphoid cells. Unlike therapeutic fludarabine, 18F-fludarabine is not used for treatment but rather for diagnostic imaging to assess tumor burden or residual disease[1][2][3][5][8].
- Other names
- fluorine-18 fludarabinefluorine18 fludarabinefluorine 18 fludarabinefludarabine F-18
02
Targets
DNA polymerase familyRNAP (Bacterial dna-dependent RNA polymerase)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on 18F-fludarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-fludarabine.